Novogen (ASX:NRT; NASDAQ: NVGN) CEO Dr James Garner talks about its licensing deal with Genentech for a drug development candidate for glioblastoma, one of the most common and aggressive forms of brain cancer. Carolyn Herbert: Hello I'm Carolyn Herbert from the Finance News Network and joining me from Novogen Limited (ASX:NRT) to discuss its licensing deal with Genentech is CEO Dr James Garner. James, welcome to FNN. James Garner: Thank you Carolyn, it's great to be here. Carolyn Herbert: Can you start by giving us a brief introduction to Novogen? James Garner: Novogen is an oncologyfocused biotechnology company; we're targeting a range of therapies for a number of different types of cancer. We are listed on the ASX, but we are also actually listed on Nasdaq; we have the advantage of being present in both countries and we have about 40 per cent of our shareholders in the United States through Nasdaq.